The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it for proteasomal degradation

Por um escritor misterioso
Last updated 27 junho 2024
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
Control of the inflammasome by the ubiquitin system - Lopez
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
Frontiers Targeting the inflammasome in Parkinson's disease
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
PDF) The ubiquitylation of IL-1β limits its cleavage by caspase-1
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
Mouse IL-1 beta /IL-1F2 Antibody (AF-401-NA): R&D Systems
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
Dendritic Cell IL-1α and IL-1β Are Polyubiquitinated and Degraded
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
IJMS, Free Full-Text
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
Cells, Free Full-Text
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
Disorders of ubiquitylation: unchained inflammation
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it  for proteasomal degradation
Cross-regulation between LUBAC and caspase-1 modulates cell death

© 2014-2024 dakarshop.net. All rights reserved.